A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer

Clinical trial NCT01959386 · COMPLETED

Trial details

NCT number: NCT01959386
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Study type: OBSERVATIONAL

Breast Neoplasms

Start date: 2013-11-07
Primary completion: 2019-01-31
Enrollment: 1006

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.